Search - tctmd.com

Displaying 1 - 20 of 60

Sort: Relevancy | Date

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

September 05, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Immediate Multivessel PCI May Not Be So Bad in STEMI Patients With Shock: DanGer Data

News Conference News EuroPCR 2025

Immediate Multivessel PCI May Not Be So Bad in STEMI Patients With Shock: DanGer Data

Yael L. Maxwell

May 20, 2025

Cost Surprises and Delayed Care in Women: BASIL-2 and BEST-CLI

News Conference News CX Symposium 2025

Cost Surprises and Delayed Care in Women: BASIL-2 and BEST-CLI

April 30, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Experts Hash Out Recommendations for Impella CP After DanGer Shock

News Conference News THT 2025

Experts Hash Out Recommendations for Impella CP After DanGer Shock

February 14, 2025

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

May 10, 2024

CLIPPER: Emphasis on Faster Revascularization Could Change CLTI Care

News Conference News CRT 2024

CLIPPER: Emphasis on Faster Revascularization Could Change CLTI Care

March 20, 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

News Conference News ISET 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

January 24, 2024

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

November 01, 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

June 21, 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

News Conference News LINC 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

June 07, 2023

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

News Conference News SCAI 2023

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

May 25, 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

News Conference News SCAI 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

May 24, 2023

BEST-CLI: Experts at ISET Look to Bridge Research Results and Practice

News Conference News ISET 2023

BEST-CLI: Experts at ISET Look to Bridge Research Results and Practice

January 25, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.